Febuxostat prevents CV events in hyperuricaemia patients

Non-Sponsored Content

ESC 2018 CONGRESS

Febuxostat prevents CV events in hyperuricaemia patients

By: News Feed | Last updated: 29th August 2018 | In: Cardiovascular, ESC 2018 Annual Congress

Article Keywords

Adenuric, allopurinol, ESC Congress, ESC18, febuxostat, gout suppressants, Ipsen, TAP Pharmaceuticals, Teijin, Uloric

Febuxostat to decrease uric acid levels and aid the prevention of cerebral, cardiovascular and renal events in elderly hyperuricaemia patients, as reported by the investigators of the FREED trial (NCT01984749) during the ESC 2018 Congress.

“We found that patients receiving febuxostat were 25 percent less likely to die or experience strokes, heart disease, or kidney disease over a three-year period than patients who did not receive febuxostat.”

~Professor Sunao Kojima, Kawasaki Medical School, Okayama, Japan

The trial randomised 1,070 higher-risk hyperuricaemia patients aged 65 years and older 1:1 to either receive up to 36 months oral febuxostat or not.

Higher risk for cerebral, cardiovascular or renal events was defined as hypertension, type 2 diabetes mellitus, renal disorders and a history of cerebral or cardiovascular disease.

The febuxostat dose was escalated stepwise from 10 to 40 mg per day based on the tolerability. Patients randomised to the non-febuxostat group received allopurinol (100 mg) if elevated serum uric acid was present. Doses of febuxostat or allopurinol were adjusted to prevent a serum uric acid level <2 mg/dL. All patients received lifestyle guidance regarding diet, smoking, and exercise.

“The findings suggest that lowering uric acid with febuxostat provides clinical benefit.”

~Professor Sunao Kojima, Kawasaki Medical School, Okayama, Japan

The primary composite endpoint included cerebral, cardiovascular, and renal events, as well as death due to any cause. In the febuxostat group, primary endpoint events occurred in 23% (125/537) of patients compared to 29% (153/533) in the non-febuxostat group. Febuxostat significantly lowered primary endpoint events (HR=0.75). Table 1 shows the effect of febuxostat vs no-febuxostat on the individual components of the primary composite endpoint.

**Table 1:** the effect of febuxostat vs no-febuxostat on the individual components of the primary composite endpoint.

*CAD: coronary artery disease; HF: heart failure; NS: non-significant.*
	Febuxostat	No-febuxostat
Renal impairment	16.2%	20.5%
Non-fatal CAD	0.7%	1.3%
HF requiring hospitalisation	1.7%	2.3%
Major cerebrocardiovascular events (NS)	1.7%	1.3%

Reference

http://www.acc.org/latest-in-cardiology/articles/2018/08/22/14/15/tues-515am-freed-esc-2018

Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

I-O in Special Populations: Chronic Viral Hepatitis Carriers

TAVR transcatheter aortic valve replacement with Portico valve reduces severe aortic stenosis in real-world study PORTICO-1

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

Transcatheter- vs surgical aortic valve replacement in high-risk patients: 5-years survival

Anti-coagulation: impact on long-term mortality and early valve dysfunction

Prof. Stephen Chan i-o-immunooncology-nivolumab-immunotherapy-hcv-hbv-reactivation-hepatitis-b-hepatitis-c-carrier

18th November 2018/by Stijn van den Borne, MSc

I-O in Special Populations: Chronic Viral Hepatitis Carriers

28th September 2018/by News Feed

Transcatheter aortic valve replacement reduces severe aortic stenosis in real-world study

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).